Retatrutide 10mg
99.4% HPLC PurityResearch-grade Retatrutide 10mg lyophilised powder. 99.4% HPLC purity, COA verified. Triple GLP-1/GIP/Glucagon receptor agonist for metabolic research.

SKU: PW-014 • Batch: PW-260710
Research-grade Tirzepatide 10mg lyophilised powder. 99.5% HPLC purity, COA verified. Dual GIP/GLP-1 receptor agonist for metabolic research.
Read the full description ↓✓Free shipping on orders over $750 AUD
✓Tracked international post — Standard $39.99 / Express $69.99 AUD
✓Dispatched next business day (orders before 11PM AEST)
Research-grade Retatrutide 10mg lyophilised powder. 99.4% HPLC purity, COA verified. Triple GLP-1/GIP/Glucagon receptor agonist for metabolic research.
Purity independently verified by an accredited third-party laboratory via HPLC & mass spectrometry.
Tirzepatide (LY3298176) is a dual receptor agonist targeting both the GIP and GLP-1 receptors. Supplied as a lyophilised powder at 99.5% HPLC purity with full Certificate of Analysis (COA) documentation.
Our Tirzepatide is sourced exclusively from GMP-certified manufacturing facilities with full chain-of-custody documentation maintained from synthesis to our Australian labs. Every batch undergoes independent third-party HPLC testing, mass spectrometry identity confirmation, LAL endotoxin assay (<1.0 EU/mg), and sterility screening before dispatch.
Research has explored Tirzepatide's simultaneous activation of the GIP and GLP-1 receptor pathways for effects on energy homeostasis, body composition, insulin sensitivity, and metabolic function, producing a distinct profile compared to single (GLP-1) receptor agonists studied in the literature.
Tirzepatide (LY3298176) is a dual GIP/GLP-1 receptor agonist investigated in preclinical and clinical research for its effects on metabolic function, body weight regulation, insulin sensitivity, and energy homeostasis. All use is strictly for in-vitro laboratory research only.
Our Tirzepatide 10mg is independently verified at 99.5% HPLC purity. Each batch is tested by an accredited third-party laboratory and comes with a full Certificate of Analysis (COA).
Lyophilised Tirzepatide should be stored at −20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.
Add bacteriostatic water (BAC water) slowly to the vial at a 1–2mL volume. Gently swirl; do not shake. Allow the lyophilised powder to dissolve completely before use in research protocols.
Tirzepatide is a dual agonist targeting the GIP and GLP-1 receptors, while Retatrutide is a triple agonist that also targets the glucagon receptor. In research settings, their differing receptor profiles produce distinct metabolic effects.
Yes. Every batch of Tirzepatide ships with a downloadable COA including HPLC purity percentage, mass spectrometry identity confirmation, sterility results, and LAL endotoxin assay data.
Tirzepatide 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable laws and regulations.
No questions yet — be the first to ask about this product.
Research-grade Retatrutide raw material, priced per gram for bulk orders. $200/gram — choose the number of grams. 99.4% HPLC purity, COA verified.
Research-grade BPC-157 (Body Protection Compound) 10mg lyophilised powder. 99.2% HPLC purity, COA verified. Stable pentadecapeptide for tissue healing and gut research.
Recent peer-reviewed studies from PubMed related to Tirzepatide. Provided for research context — not medical advice.
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff AM, le Roux CW, Stefanski A, et al. · The New England journal of medicine · 2025
PMID: 39536238
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne LJ, Horn DB, le Roux CW, et al. · The New England journal of medicine · 2025
PMID: 40353578
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey WT, Frias JP, Jastreboff AM, et al. · Lancet (London, England) · 2023
PMID: 37385275
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Loomba R, Hartman ML, Lawitz EJ, et al. · The New England journal of medicine · 2024
PMID: 38856224
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.